Lalit Batra

PeerJ Author & Reviewer

Summary

Dr. Lalit Batra is a Research Scientist within the Center for Predictive Medicine at the University of Louisville.

His research interests/output includes:

- Evaluation of efficacy Q-Griffithsin and AS1411 against SARS-CoV2 infection in hamsters, ferrets and hACE2 mice.
- Cancer Immunoprevention using a novel CD137 receptor agonist SA-4-1BBL molecule.
- Evaluated and published the role of novel SA-4-1BBL molecule as stand-alone monotherapeutics agent for Cancer Immunoprevention against TC-1, huMUC-1 and 3LL mouse tumor models.
- Evaluating the monotherapeutic role of SA-4-1BBL molecule against variety of tumor models such as melanoma, lymphoma, breast cancer and spontaneous cancer models.
- Vaccine approaches using SA-4-1BBL molecule against Yersinia pestis Infection (ABSL3).
- Evaluated and published the role of SA-4-1BBL as an adjuvant with the lead Y. pestis antigen (rF1-V) against lethal pneumonic plague challenge in BALB/c and C57BL/6 mice.
- Development of immunomodulatory protocols for overcoming allograft rejection for Type I Diabetes Mellitus (T1D).
- Evaluated and published the efficacy of immunomodulatory molecules such as SA-PDL1, SA-FasL and SA-CD47 for prevention of allograft rejection in chemically diabetic Mouse models.
- Evaluating the efficacy of SA-FasL for reversal of diabetes in recent-onset NOD mice.

Agricultural Science Allergy & Clinical Immunology Biotechnology Cell Biology Clinical Trials COVID-19 Diabetes & Endocrinology Epidemiology Food Science & Technology Gastroenterology & Hepatology Genetics Genomics Healthcare Services Hematology Histology Immunology Infectious Diseases Mental Health Microbiology Molecular Biology Parasitology Pharmacology Plant Science Public Health Translational Medicine Tuberculosis Veterinary Medicine Virology Zoology

Work details

Research Scientist

Uni of Louisville

November 2015

Center for Predective Medicine

1. Evaluation of efficacy Q-Griffithsin and AS1411 against SARS-CoV2 infection in hamsters, ferrets and hACE2 mice. 2. Cancer Immunoprevention using a novel CD137 receptor agonist SA-4-1BBL molecule • Evaluated and published the role of novel SA-4-1BBL molecule as stand-alone monotherapeutics agent for Cancer Immunoprevention against TC-1, huMUC-1 and 3LL mouse tumor models. • Evaluating the monotherapeutic role of SA-4-1BBL molecule against variety of tumor models such as melanoma, lymphoma, breast cancer and spontaneous cancer models. 3. Vaccine approaches using SA-4-1BBL molecule against Yersinia pestis Infection (ABSL3) • Evaluated and published the role of SA-4-1BBL as an adjuvant with the lead Y. pestis antigen (rF1-V) against lethal pneumonic plague challenge in BALB/c and C57BL/6 mice. 4. Development of immunomodulatory protocols for overcoming allograft rejection for Type I Diabetes Mellitus (T1D) • Evaluated and published the efficacy of immunomodulatory molecules such as SA-PDL1, SA-FasL and SA-CD47 for prevention of allograft rejection in chemically diabetic Mouse models. • Evaluating the efficacy of SA-FasL for reversal of diabetes in recent-onset NOD mice.